
Chris
Xu, Ph.D., is the current president and chairman of Boyalife
Group, which he founded in 2009. Prior to founding Boyalife,
Dr. Xu served as a project leader at Pfizer, as a director
of research at two publicly-traded biopharmaceutical
companies and as a vice president at Founder Group, a
Chinese technology conglomerate focused on information
technology, pharmaceuticals, real estate, finance, and
commodities trading. Dr. Xu’s expertise spans several
diverse therapeutic areas, including arthritis &
inflammation, cardiovascular disease, autoimmunity, oncology
and diabetes. He has authored over forty publications and
has been recognized by numerous professional societies for
his contributions to biomedical research. Dr. Xu received
his Ph.D. in immunology from Washington University School of
Medicine (St. Louis, USA) and an executive MBA from Emory
University (Atlanta, USA).